Food and Drug Administration

Food Advisory Committee

June 7-8, 2004


Questions, Dr. Laura Tarantino, PhD, FDA (HTM) (PPT)

Legal Framework, Louisa Nickerson, FDA (HTM) (PPT)

Overview of Scientific Issues, Dr. J. Rowlands, PhD, FDA (HTM) (PPT)

Glucosamine and Chondroitin Sulfate Reduce Risk of Osteoarthritis, Dr. Luke Bucci, PhD, Weider Nutrition Group (HTM) (PPT)

Osteoarthritis: Etiology, Pathogenesis and Treatment Considerations, Dr. Lee Simon, MD, Harvard Medical School (HTM) (PPT)

Osteoarthritis (OA): In Vitro and Animal Models, Dr. James Witter, MD, PhD, FDA (HTM) (PPT)

In Support of OA Health Claims for Glucosamine & Chondroitin, Dr. Jason Theodosakis, MD, MS, MPH, FACPM, University of Arizona College of Medicine (HTM) (PPT)

Chondroitin Sulfate: Clinical Review in Osteoarthritis, Dr. José Vergés, MD, MSc, PhD (HTM) (PPT)

Chondroitin Sulfate - Clinical Review in Osteoarthritis, Background (PDF)

Presentation by Nutramax Laboratories, Inc. (HTM) (PPT)

Written Statement by Dr. Bob Arnot (HTM) (PDF) (Word)

The Osteoarthritis Initiative, Gayle Lester, PhD (PDF)

Crystalline Glucosamine Sulfate - Introduction, Rotta Pharmaceuticals, Inc. (PDF)

Questions for the Glucosamine & Chondroitin Sulfate (G&CS) and Osteoarthritis (OA) Food Advisory Committee, Rotta Pharmaceuticals, Inc. (PDF)